ACALABRUTINIB
Information current as at: 1 March 2025
PBAC meeting date: November 2021
Submission Details
- Brand name:
-
- Calquence®
- Pharmaceutical company:
- AstraZeneca Pty Ltd
- Condition/indication:
(therapeutic use) -
- Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
- PBAC Submission type:
- Change to listing (–)
- Comment:
- --
- Public Summary Document:
- Public Summary Documents – November 2021
- Related medicines:
Progress Details
-
Submission received for: - November 2021 PBAC meeting
-
Opportunity for consumer comment: - Open 28/07/2021 and close 22/09/2021 (see PBS Website)
-
PBAC meeting: - Held on 03/11/2021
-
PBAC outcome published: - Not Recommended (see PBAC Outcomes)
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
Case ID: a390
Page last updated: 31 October 2024